Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on CDW, Raises Price Target to $200

Morgan Stanley analyst Katy Huberty maintains CDW (NASDAQ:CDW) with a Equal-Weight and raises the price target from $196 to $200.

byBenzinga Newsdesk

November 4, 2021

1 minute read

Morgan Stanley analyst Katy Huberty maintains CDW (NASDAQ:CDW) with a Equal-Weight and raises the price target from $196 to $200.

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $236

By Benzinga Newsdesk

Today, 2:17 AM

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $240 to $236.

ALNY

Helbiz Shares Skyrocket On Partnership With FOX Networks

By Shivani Kumaresan

Today, 2:17 AM

Helbiz Inc (NASDAQ:HLBZ) has announced an agreement between its media unit and FOX Networks Group, a subsidiary of Walt Disney Co (NYSE:DIS), to…

DIS

Stifel Maintains Hold on Cognyte Software, Lowers Price Target to $3

By Benzinga Newsdesk

Today, 2:17 AM

Stifel analyst Brad Reback maintains Cognyte Software (NASDAQ:CGNT) with a Hold and lowers the price target from $6 to $3.

CGNT

Facebook Parent Said To Splurge $60M On Meta Naming Rights

By Shivdeep Dhaliwal

Today, 2:17 AM

Facebook Inc (NASDAQ: FB), which is undergoing metamorphosis into Meta Platforms Inc, reportedly dished out $60 million to acquire trademark assets from Meta Financial Group (NASDAQ: CASH).

AAPL

Morgan Stanley Maintains Equal-Weight on CDW, Raises Price Target to $200

Related Posts

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $236

Helbiz Shares Skyrocket On Partnership With FOX Networks

Stifel Maintains Hold on Cognyte Software, Lowers Price Target to $3

Facebook Parent Said To Splurge $60M On Meta Naming Rights